# Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy

> **NCT07266181** · PHASE1 · RECRUITING · sponsor: **The First Affiliated Hospital of Air Force Medicial University** · enrollment: 5 (estimated)

## Conditions studied

- Refractory Membranous Nephropathy

## Interventions

- **OTHER:** All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.

## Key facts

- **NCT ID:** NCT07266181
- **Lead sponsor:** The First Affiliated Hospital of Air Force Medicial University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2027-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07266181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07266181, "Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07266181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*